NREP
NEW REPRESENTATIVE AT IB RECEIVED
01/11/2024
Voltar para busca
Dado oficial do USPTO
FLORATEK
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
31
Atualização mais recente
01/11/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
13/10/2021
Data de registro
06/06/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
06/06/2023
Última transação
06/06/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
33
Localização do titular
Aubonne, CH
Examinador
CANTOR, JILLIAN
Unidade examinadora
M80
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Floratek Pharma SA
Representantes
Diane B. Melnick Practus LLP
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical products for the prevention and treatment of cancer; pharmaceutical preparations, namely a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; medicinal preparations for the treatment of infectious diseases and for use in oncology; therapeutic preparations for treating cardiovascular diseases; pharmaceutical and medicinal preparations and substances for the treatment of diabetes; pharmaceutical and medicinal preparations and substances for use in oncology; pharmaceutical and medicinal preparations, substances and compositions for the treatment and/or prevention of cancer; pharmaceutical and medicinal preparations and substances for the treatment of neurodegenerative disorders; pharmaceutical and medicinal preparations and substances for the treatment of metabolic disorders; pharmaceutical and medicinal preparations and substances for the treatment of musculoskeletal disorders; pharmaceutical and medicinal preparations and substances for the treatment of osteoarthritis; pharmaceutical and medicinal preparations and substances for the treatment of genetic disorders and rare diseases
Classe 42
Scientific research; pharmaceutical research; medical research services in the field of medicines; technical advice for third parties in the field of development of pharmaceutical products; product development for third parties in the field of pharmaceutical products; research and development of pharmaceuticals and medicinal preparations and substances for third parties; research and development of pharmaceuticals and medicinal preparations and substances for the treatment of cancer; research and development of pharmaceuticals and medicinal preparations and substances for treating inflammation; research and development of pharmaceuticals and medicinal preparations and substances for the treatment of neurodegenerative disorders; research and development of pharmaceutical and medicinal preparations and substances for the treatment of metabolic disorders; research and development of pharmaceutical and medicinal preparations and substances for the treatment of musculoskeletal disorders; research and development of pharmaceutical and medicinal preparations and substances for the treatment of osteoarthritis; research and development of pharmaceutical and medicinal preparations and substances for the treatment of genetic disorders and rare diseases
Publicações
Histórico de despachos e eventos da marca no USPTO.
31 publicações encontradas
NREP
NEW REPRESENTATIVE AT IB RECEIVED
06/09/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/10/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
07/09/2023
FIMP
FINAL DISPOSITION PROCESSED
07/09/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/09/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/06/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
06/06/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
05/06/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
17/05/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
17/05/2023
GPNX
NOTIFICATION PROCESSED BY IB
21/03/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
21/03/2023
PUBO
PUBLISHED FOR OPPOSITION
21/03/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/03/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/03/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/03/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
14/02/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/02/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/02/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/02/2023
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
05/02/2023
RFNT
REFUSAL PROCESSED BY IB
29/08/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
11/08/2022
RFRR
REFUSAL PROCESSED BY MPU
11/08/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
21/07/2022
CNRT
NON-FINAL ACTION WRITTEN
20/07/2022
DOCK
ASSIGNED TO EXAMINER
19/07/2022
MAFR
APPLICATION FILING RECEIPT MAILED
24/12/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
20/12/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
16/12/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace FLORATEK ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.